Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Lowered to $41.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its price objective lowered by Piper Sandler from $45.00 to $41.00 in a research note released on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy […]
More Stories
What a New Roof Really Costs in Texas: A 2026 Budget Guide
The roof is the most expensive part of a house that most owners never look at. One spring storm can...
Haunted Hotel Season 3: Netflix Release Date, Cast, Plot, and More
If you are a fan of anime movies and series, this blog is for you! Popular 2025 American adult animated...
Massive Alaska North Slope Gas Discovery Could Power US for Nearly 3 Years
By Naveen Athrappully Alaska’s North Slope region could contain 96 trillion cubic feet of undiscovered and technically recoverable natural gas...
UK Must Be Ready for War in 1,000 Days, Says British Defense Secretary
By Rachel Roberts British Defense Secretary Wes Streeting has said the country must be ready for war in 1,000 days,...
Trump Offers $1 Million to Anyone Who Reports Voter Fraud Leading to Conviction
By Jack Phillips President Donald Trump on Monday said that he would provide $1 million to people who can report...
Federal Judge Strikes Down New York Body Armor Ban
By Jack Phillips A federal judge this past week overturned New York state’s ban on the sale and purchase of...